Title: Characteristics of triple-negative breast cancer in patients with a BRCA1 mutation: results from a population-based study of young women.
Authors: Lee, Eunjung; McKean-Cowdin, Roberta; Ma, Huiyan; Spicer, Darcy V; Van Den Berg, David; Bernstein, Leslie; Ursin, Giske
Published In J Clin Oncol, (2011 Nov 20)
Abstract: Triple-negative breast cancers (TNBCs) are tumors with low or no expression of estrogen receptor, progesterone receptor, or human epidermal growth factor receptor 2. These tumors have a poor prognosis, remain a clinical challenge, and are more common among women with BRCA1 mutations. We tested whether there are distinguishing features of TNBC after BRCA1 mutation status has been taken into account.We sequenced BRCA1 and BRCA2 genes in a population-based sample of 1,469 patients with incident breast cancer age 20 to 49 years from Los Angeles County (California). Information on tumor receptor status was available for 1,167 women. Clinical, pathologic, and hormone-related lifestyle characteristics were compared across patient subgroups defined by BRCA1 mutation status and triple-negative receptor status.Forty-eight percent of BRCA1 mutation carriers had TNBC compared with only 12% of noncarriers. Within BRCA1 mutation carriers, as well as within noncarriers, triple-negative receptor status was associated with younger age at diagnosis and higher tumor grade. Among women without a BRCA1 mutation, we observed that women with TNBC had higher premenopausal body mass index and earlier age at first full-term pregnancy than those with non-TNBC. Age at menarche and other reproductive factors were not associated with triple-negative status regardless of BRCA1 mutation status. Within BRCA1 mutation carriers, Ashkenazi Jewish women were about five times more likely to have TNBC than non-Ashkenazi Jewish women.Our results suggest that among BRCA1 mutation carriers, as among noncarriers, there are unique characteristics associated with the triple-negative subtype. The findings in Ashkenazi Jewish BRCA1 mutation carriers should be confirmed.
PubMed ID: 22010008
MeSH Terms: Adult; Breast Neoplasms/chemistry; Breast Neoplasms/genetics*; Female; Genes, BRCA1*; Germ-Line Mutation*; Humans; Middle Aged; Receptor, ErbB-2/analysis; Receptors, Estrogen/analysis; Receptors, Progesterone/analysis; Young Adult